Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma.
Hepatocellular carcinoma (HCC) has variable 18F-fluoro-2-deoxy-D-glucose (18F-FDG) uptake and the relationship between 18F-FDG uptake with the expression of glucose transporters (Gluts) and hexokinase II (HK-II) has not been extensively examined. Present study explored the role of 18F-FDG positron emission tomography (PET) as a clinical significance and the association with Gluts and HK-II in patients with HCC. Whole body 18F-FDG PET, immunohistochemistry and western blot analysis of Glut-1 to Glut-5 and HK-II were performed in 31 patients (24 male and 7 female, range 48-75 years) with HCC. Significant correlation was found between 18F-FDG uptake and overall expression of Glut-2 (rho=0.55, p=0.002) and HK-II (rho=0.37, p=0.04). Expression of HK-II was correlated with Glut-2 (rho=0.57, p=0.0009) but not with other Gluts, which indicated that Glut-2 is a major glucose transporter. The prognosis of patients with SUV >/=2 and positive Glut-2 were significantly worse than that with SUV <2 and negative Glut-2 (p=0.005 and p=0.03), respectively. Multivariate analysis showed that SUV and lymph node metastasis were independent prognostic factors. The present study indicated that combined evaluation of 18F-FDG uptake and expression of Glut-2 might have an important role for management of patients with HCC.
Paudyal
Bishnuhari
B
Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan. paudyal@med.gunma-u.ac.jp
Paudyal
Pramila
P
Oriuchi
Noboru
N
Tsushima
Yoshito
Y
Nakajima
Takashi
T
Endo
Keigo
K
D000368:Aged; D015153:Blotting, Western; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000401:mortality / Q000628:therapy; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism; D005947:Glucose / Q000378:metabolism*; D051246:Glucose Transport Proteins, Facilitative / Q000378:metabolism*; D051273:Glucose Transporter Type 2 / Q000378:metabolism; D006593:Hexokinase / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D016016:Proportional Hazards Models; D019275:Radiopharmaceuticals / Q000378:metabolism; D018570:Risk Assessment; D016896:Treatment Outcome
D051246:Glucose Transport Proteins, Facilitative; D051273:Glucose Transporter Type 2; D019275:Radiopharmaceuticals; C495680:SLC2A2 protein, human; D019788:Fluorodeoxyglucose F18; D006593:Hexokinase; D005947:Glucose